

17 November 2021

ASX Announcement

Results of Annual General Meeting

MELBOURNE Australia, 17 November 2021: Australian mid-clinical stage antiviral drug repurposing company, Island Pharmaceuticals Ltd (ASX: ILA) advises that its Annual General Meeting was held today at 11.30 am AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

Approved for release to the ASX by:

Dr Paul MacLeman
Executive Chairman
Isla Pharmaceuticals
info@islandpharmaceuticals.com

For further information, please contact:

Investors: Jane Lowe IR Department Mobile: +61 411 117 774 jane.lowe@irdepartment.com.au	Media: Juliana Roadley IR Department Mobile: +61 414 889 863 juliana.roadley@irdepartment.com.au
--	--

About Island Pharmaceuticals

Island is clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. The Company is advancing toward a Phase II clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Isla may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) would permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.

Disclosure of Proxy Votes

Island Pharmaceuticals Limited

Annual General Meeting 2021

Wednesday, 17 November 2021



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	35,630,885	35,571,885 99.83%	15,000 0.04%	1,857,947	44,000 0.12%	35,647,385 99.96%	15,000 0.04%	1,857,947
2 Re-election of Paul MacLeman	P	53,414,498	53,370,498 99.92%	0 0.00%	110,000	44,000 0.08%	53,531,051 100.00%	0 0.00%	110,000
3 Re-election of David Brookes	P	53,414,498	53,370,498 99.92%	0 0.00%	110,000	44,000 0.08%	53,531,051 100.00%	0 0.00%	110,000
4 Approval of increased placement capacity	P	51,666,551	51,605,221 99.88%	17,330 0.03%	1,857,947	44,000 0.09%	51,734,274 99.97%	17,330 0.03%	1,889,447
5 Issue of shares to David Brookes or his nominee in accordance with Listing Rule 10.11	P	53,414,498	53,368,168 99.91%	2,330 0.00%	110,000	44,000 0.08%	53,528,721 100.00%	2,330 0.00%	110,000
6 Issue of shares to Anna Lavelle or her nominee in accordance with Listing Rule 10.11	P	51,666,551	51,620,221 99.91%	2,330 0.00%	1,857,947	44,000 0.09%	51,780,774 100.00%	2,330 0.00%	1,857,947
7 Issue of shares to Albert Hansen or his nominee in accordance with Listing Rule 10.11	P	53,414,498	40,782,854 76.35%	1,750,277 3.28%	110,000	10,881,367 20.37%	40,943,407 95.90%	1,750,277 4.10%	110,000

